Zacks Investment Research Lowers Oxford Biomedica (OXBDF) to Hold
Zacks Investment Research cut shares of Oxford Biomedica (NASDAQ:OXBDF) from a buy rating to a hold rating in a research note published on Wednesday.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
Shares of Oxford Biomedica (NASDAQ OXBDF) opened at 0.117 on Wednesday. Oxford Biomedica has a 12-month low of $0.04 and a 12-month high of $0.15. The company’s 50 day moving average is $0.12 and its 200 day moving average is $0.12. The company’s market capitalization is $361.33 million.
ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers Oxford Biomedica (OXBDF) to Hold” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/09/zacks-investment-research-lowers-oxford-biomedica-oxbdf-to-hold.html.
About Oxford Biomedica
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related stocks with our FREE daily email newsletter.